Idex (IEX) Reports Q3 Earnings: Key Metrics Insight

For the third quarter ending in September 2024, Idex (IEX - Free Report) reported a revenue of $798.2 million. This reflects a modest increase of 0.6% compared to the same quarter last year. In terms of earnings per share (EPS), the company reported $1.90, a decrease from $2.12 in the previous year’s quarter.

The reported revenue surpassed the Zacks Consensus Estimate of $790.95 million by 0.92%. Moreover, the EPS exceeded the consensus estimate of $1.89, resulting in a surprise of 0.53%.

While revenue and earnings figures offer a snapshot of Idex’s performance, investors should also pay attention to several important metrics that provide deeper insights into the company's operations. These metrics can significantly influence both the top and bottom lines, making it essential to compare them against year-over-year numbers and Wall Street’s expectations.

Here’s a breakdown of how Idex performed in the latest quarter based on some key metrics that analysts frequently monitor:

• Net sales - Fluid & Metering Technologies: $300.80 million, surpassing the average estimate of $295.31 million from three analysts. This represents a slight decline of 0.1% from the previous year.
• Intersegment sales eliminations: -$1.60 million, compared to the average estimate of -$1.26 million from three analysts, showing a year-over-year increase of 6.7%.
• Net sales - Fire & Safety / Diversified Products: $188 million, exceeding the three-analyst average estimate of $182.22 million, marking a year-over-year growth of 4.1%.
• Net sales - Health & Science Technologies: $311 million, which is below the average estimate of $319.03 million from three analysts. This indicates a slight decline of 0.7% compared to the prior year.
• Adjusted EBITDA - FMT (Fluid & Metering Technologies): $98.50 million, compared to an estimate of $98.70 million based on two analysts.
• Adjusted EBITDA - Corporate: -$21.50 million, slightly better than the estimate of -$21.90 million among two analysts.
• Adjusted EBITDA - FSDP (Fire & Safety / Diversified Products): $54.70 million, outperforming the average estimate of $51.40 million from two analysts.
• Adjusted EBITDA - HST (Health & Science Technologies): $82.60 million, below the estimate of $86.90 million based on two analysts.

Tracking these metrics is critical for investors as they can provide a clearer picture of a company’s operational effectiveness and future potential.

In terms of stock performance, shares of Idex have experienced a decline of 4.5% over the past month, contrasting with a 1.7% increase in the Zacks S&P 500 composite. Currently, the stock holds a Zacks Rank of #3 (Hold), suggesting it may perform in line with the overall market in the near term.

Idex, Earnings, Metrics